---
title: "Brief News: Tianxing Medical's midday increase of 132% exceeds 7,800 times"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285162885.md"
description: "Medical device company Beijing Tianxing Medical Co., Ltd. debuted on Tuesday, opening at HKD 288, up 192% from the offering price, and closing at noon up 132%. The company offered 8.422 million shares at a price of HKD 98.5 per share, raising a net amount of HKD 758 million. The public offering was oversubscribed by 7,822 times, and the international placement was oversubscribed by 9.4 times. In 2024, based on sales revenue, Tianxing Medical is the fourth largest provider of sports medicine implants and devices in China, with a market share of approximately 6.5%. Last year's revenue was HKD 403 million, an increase of 23% year-on-year; net profit was HKD 137 million, up 44% year-on-year. The funds raised will be used to expand productivity, research and development, and marketing"
datetime: "2026-05-05T06:35:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285162885.md)
  - [en](https://longbridge.com/en/news/285162885.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285162885.md)
---

# Brief News: Tianxing Medical's midday increase of 132% exceeds 7,800 times

Medical device company **Beijing Tianxing Medical Co., Ltd.** (1609.HK) debuted on Tuesday, opening at HKD 288, up 192% from the offering price. The stock price later softened, closing at a 132% increase at noon.

The company offered 8.422 million shares at a price of HKD 98.5 per share, raising a net amount of HKD 758 million. The public offering was oversubscribed by **7,822 times**, and the international placement was oversubscribed by 9.4 times.

In 2024, based on sales revenue, Tianxing Medical is the fourth largest provider of sports medicine implants and devices in China, with a market share of approximately 6.5%. Last year, the company's revenue was HKD 403 million, an increase of 23% year-on-year; it earned HKD 137 million, a year-on-year increase of 44%.

Of the funds raised, 30% will be used to expand productivity and efficiency, 35% for research and development, 25% for commercialization, sales, and marketing, and the remaining 10% as general working capital.

_Liu Zhiheng_

### Related Stocks

- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [512170.CN](https://longbridge.com/en/quote/512170.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [159883.CN](https://longbridge.com/en/quote/159883.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [562600.CN](https://longbridge.com/en/quote/562600.CN.md)

## Related News & Research

- [Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium](https://longbridge.com/en/news/286258287.md)
- [Broncus shareholders back all AGM resolutions, update articles of association](https://longbridge.com/en/news/286439966.md)
- [DOJ Launches Criminal Probe Into Blue State Hospital](https://longbridge.com/en/news/286157785.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)